Xu Sun

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial

Lionnel Geoffrois, Laurent Martin, D. De Raucourt et al. · Journal of Clinical Oncology · 2018 · 148 citations

Medicine, Oncology, Radiation Oncology +15

Photodynamic therapy produces enhanced efficacy of antitumor immunotherapy by simultaneously inducing intratumoral release of sorafenib

Xu Sun, Ziyang Cao, Kuirong Mao et al. · Biomaterials · 2020 · 82 citations

Medicine, Immunology, Oncology +12

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial

Yungan Tao, Anne Aupérin, Christian Sire et al. · Journal of Clinical Oncology · 2018 · 77 citations

Medicine, Oncology, Radiation Oncology +10

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Sun, Christian Sire, Yungan Tao et al. · Journal of Clinical Oncology · 2018 · 53 citations

Medicine, Oncology, Radiation Oncology +14

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Jean Bourhis, Anne Aupérin, Christian Borel et al. · Journal of Clinical Oncology · 2025 · 53 citations

Medicine, Oncology, Surgery +17